Marit Kristiansen

This inventor holds 22 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents, primarily in Glucokinase Activators. Top assignees: Novo Nordisk A/s, Novo Nordick A/s. Active years: 1992-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marit Kristiansen. Retrieved from https://idiyas.com/inventor/marit-kristiansen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 1)

% Patents Active = 59.1

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 4.3

ph-index = 9

Forward Citations = 434(Granted Patents)

Location History:

S.o slashed.borg, DK (1999 - 2000)
Søborg, DK (2003 - 2012)
Soborg, DK (1992 - 2013)
Soeborg, DK (1998 - 2014)

Company Filing History:

Years Active: 1992-2014

Loading Chart...

Areas of Expertise:

Glucokinase Activators

Heteroaryl-Ureas

Dicycloalkylcarbamoyl Ureas

Heterocyclic Compounds

DPP-IV Inhibitors

Glycogen Phosphorylase

Pyrrolidine Compounds

Imidazoquinazoline

Piperazinyl Derivatives

Aromatic Compounds

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE45183 - Heteroaryl-ureas and their use as glucokinase activators (2014-10-06),

2. 8586614 - Urea glucokinase activators (2013-11-19),

3. 8263634 - Heteroaryl-ureas and their use as glucokinase activators (2012-09-11),

4. 8148412 - Heteroaromatic glucokinase activators (2012-04-03),

5. 7999114 - Dicycloalkylcarbamoyl ureas as glucokinase activators (2011-08-16),

6. 7884210 - Ureido-thiazole glucokinase activators (2011-02-08),

7. 7872139 - Heteroaryl-ureas and their use as glucokinase activators (2011-01-18),

8. 7851636 - Heteroaryl-ureas and their use as glucokinase activators (2010-12-14),

9. 7598391 - Heteroaryl-ureas and their use as glucokinase activators (2009-10-06),

10. 7582769 - Dicycloalkyl urea glucokinase activators (2009-09-01),

11. 7235538 - Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV (2007-06-26),

12. 7192952 - Heterocyclic compounds that are inhibitors of the enzyme DPP-IV (2007-03-20),

13. 6960610 - Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases (2005-11-01),

14. 6869947 - Heterocyclic compounds that are inhibitors of the enzyme DPP-IV (2005-03-22),

15. 6590118 - Aromatic compounds (2003-07-08),

Title: Unveiling the Inventive Journey of Marit Kristiansen from Soborg, DK

Introduction:

Marit Kristiansen, a prolific inventor hailing from Soborg, DK, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 22 patents. His groundbreaking work revolves around the development of novel compounds aimed at enhancing glucokinase activity for the treatment of various diseases, particularly type 2 diabetes.

Latest Patents:

Marit Kristiansen's recent patents showcase his expertise in the creation of innovative pharmaceutical solutions. One such patent involves Heteroaryl-ureas designed as glucokinase activators (formula I), which play a crucial role in managing diseases where boosting glucokinase activity is advantageous. Additionally, the invention of Urea glucokinase activators highlights his commitment to advancing treatments for type 2 diabetes and other related conditions.

Career Highlights:

Having worked with renowned companies such as Novo Nordisk A/S, Marit Kristiansen has honed his skills and expertise in the pharmaceutical industry. His tenure at Novo Nordisk A/S has been instrumental in translating his innovative ideas into tangible patents that have the potential to revolutionize the treatment landscape for various medical conditions.

Collaborations:

Throughout his career, Marit Kristiansen has collaborated with esteemed professionals in the field, including Jane Marie Lundbeck and Lone Jeppesen. These collaborations have not only enriched his inventive process but have also fostered a culture of innovation and excellence within the industry.

Conclusion:

In conclusion, Marit Kristiansen stands as a trailblazing inventor whose dedication to advancing pharmaceutical solutions has led to the development of groundbreaking patents in the realm of glucokinase activators. His contributions underscore the importance of innovation in addressing complex medical challenges, paving the way for enhanced treatment options and improved patient outcomes.

Profile summary based on public USPTO records.